Asset
EXALUREN
Eloxx Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04069260 | phase2 | terminated | 2019-08-02 | 2019-12-17 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis |
| NCT04126473 | phase2 | completed | 2019-11-05 | 2022-04-06 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele |
| NCT04135495 | phase2 | completed | 2019-11-25 | 2022-10-03 | Eloxx Pharmaceuticals, Inc. | A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele |
| NCT05448755 | phase2 | completed | 2022-11-28 | 2023-09-11 | Eloxx Pharmaceuticals, Inc. | A Study of ELX-02 in Patients With Alport Syndrome |
| NCT03776539 | phase1 | completed | 2019-01-04 | 2019-07-30 | Eloxx Pharmaceuticals, Inc. | A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02 |
FDA applications (0)
This company has no applications containing this asset.